Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
3 vials (9 mL): 1 bottle 5 vials (15 mL): 2 bottles 6 vials (18 mL): 2 bottles Alcohol Swabs One for the vial stopper + one for the injection site each day
At-home microinfusion copies the same architectural principle, including the MicroInfuser, at a shallower 0.5mm depth that is safer for unsupervised self-administration
Do not accept the "Zombie" state
Mobile IV therapy vs urgent care compared on cost, wait times, and use cases in Arizona
Like astrocytes, pericytes release various factors that upregulate the expression of tight junction proteins in vitro [112]